
About Acute Myeloid Leukemia (AML)

Get an overview of acute myeloid leukemia and the latest key statistics in the US.

Overview of AML

If you have been diagnosed with acute myeloid leukemia or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start.

- [What Is Acute Myeloid Leukemia \(AML\)?](#)

Research and Statistics

See the latest estimates for new cases of acute myeloid leukemia and deaths in the US and what research is currently being done.

- [Key Statistics for Acute Myeloid Leukemia \(AML\)](#)
- [What's New in Acute Myeloid Leukemia \(AML\) Research?](#)

What Is Acute Myeloid Leukemia (AML)?

- [Normal bone marrow, blood, and lymph tissue](#)

Cancer starts when cells in a part of the body begin to grow out of control. There are

many kinds of cancer. Cells in nearly any part of the body can become cancer. To learn more about cancer and how it starts and grows, see [What Is Cancer?](#)¹

Leukemias are cancers that start in cells that would normally develop into different types of blood cells. Most often, leukemia starts in early forms of white blood cells, but some leukemias start in other blood cell types. There are several types of leukemia, which are divided based mainly on whether the leukemia is acute (fast growing) or chronic (slower growing), and whether it starts in myeloid cells or lymphoid cells.

Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but most often it quickly moves into the blood, as well. It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles.

Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. The different types of AML are discussed in [Acute Myeloid Leukemia \(AML\) Subtypes and Prognostic Factors](#)².

Acute myeloid leukemia (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.

Normal bone marrow, blood, and lymph tissue

To understand leukemia, it helps to know about the blood and lymph systems.

Bone marrow

Bone marrow is the soft inner part of certain bones. It is made up of blood-forming cells, fat cells, and supporting tissues. A small fraction of the blood-forming cells are **blood stem cells**.

Inside the bone marrow, blood stem cells develop into new blood cells. During this process, the cells become either lymphocytes (a kind of white blood cell) or other blood-forming cells, which are types of **myeloid cells**. Myeloid cells can develop into red blood cells, white blood cells (other than lymphocytes), or platelets. These myeloid cells are the ones that are abnormal in AML.

Types of blood cells

There are 3 main types of blood cells:

- **Red blood cells (RBCs)** carry oxygen from the lungs to all other tissues in the body, and take carbon dioxide back to the lungs to be removed.
- **Platelets** are actually cell fragments made by a type of bone marrow cell called the megakaryocyte. Platelets are important in stopping bleeding. They help plug up holes in blood vessels caused by cuts or bruises.
- **White blood cells (WBCs)** help the body fight infections.

There are different types of WBCs:

- **Granulocytes** are mature WBCs that develop from myeloblasts, a type of blood-forming cell in the bone marrow. Granulocytes have granules that show up as spots under the microscope. These granules contain enzymes and other substances that can destroy germs, such as bacteria. The 3 types of granulocytes – **neutrophils**, **basophils**, and **eosinophils** – are distinguished by the size and color of their granules.
- **Monocytes** are WBCs that develop from blood-forming monoblasts in the bone marrow. After circulating in the bloodstream for about a day, monocytes enter body tissues to become **macrophages**, which can destroy some germs by surrounding and digesting them. Macrophages also help lymphocytes recognize germs and make antibodies to fight them.
- **Lymphocytes** are mature WBCs that develop from lymphoblasts in the bone marrow. Lymphocytes are the main cells that make up lymph tissue, a major part of the immune system. Lymph tissue is found in lymph nodes, the thymus (a small organ behind the breast bone), the spleen, the tonsils and adenoids, and is scattered throughout the digestive and respiratory systems and the bone marrow. The 2 main types of lymphocytes are B cell and T cells.

Hyperlinks

1. www.cancer.org/cancer/understanding-cancer/what-is-cancer.html
2. www.cancer.org/cancer/types/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.html
3. www.cancer.org/cancer/types/leukemia-in-children.html

References

Kolitz JE. Overview of acute myeloid leukemia in adults. UpToDate. 2018. Accessed at www.uptodate.com/contents/overview-of-acute-myeloid-leukemia-in-adults on June 12, 2018.

National Cancer Institute. Physician Data Query (PDQ). Adult Acute Myeloid Leukemia Treatment. 2018. Accessed at www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq on June 12, 2018.

Raffel GD, Cerny J. Chapter 106: Molecular Biology of Acute Leukemias. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Last Revised: August 21, 2018

Key Statistics for Acute Myeloid Leukemia (AML)

The American Cancer Society's estimates for leukemia in the United States for 2024 are:

- About 62,770 new cases of leukemia (all kinds) and 23,670 deaths from leukemia (all kinds)
- About 20,800 new cases of acute myeloid leukemia (AML). Most will be in adults.
- About 11,220 deaths from AML. Almost all will be in adults.

AML is one of the most common types of leukemia in adults. Still, AML is fairly rare overall, accounting for only about 1% of all cancers.

AML is generally a disease of older people and is uncommon before the age of 45. The average age of people when they are first diagnosed with AML is about 68. But [AML can occur in children](#)¹ as well.

AML is slightly more common among men than women, but the average lifetime risk of

getting AML for both sexes is about ½ of 1%.

Information on treatment success rates for AML in adults can be found in [Treatment Response Rates for Acute Myeloid Leukemia](#)².

Visit the [American Cancer Society's Cancer Statistics Center](#)³ for more key statistics.

Hyperlinks

1. www.cancer.org/cancer/types/leukemia-in-children.html
2. www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/response-rates.html
3. cancerstatisticscenter.cancer.org/

References

American Cancer Society. *Cancer Facts & Figures 2024*. Atlanta : American Cancer Society; 2024.

National Cancer Institute. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Accessed at <https://seer.cancer.gov/statfacts/html/amyl.html> on June 12, 2018.

Last Revised: January 17, 2024

What's New in Acute Myeloid Leukemia (AML) Research?

- [Genetics of AML](#)
- [Improving treatment](#)

Researchers continue to study the causes, diagnosis, and treatment of acute myeloid

leukemia (AML) at many medical centers, university hospitals, and other institutions around the world.

Genetics of AML

There continues to be progress in understanding how normal bone marrow cells can develop into leukemia cells. It has become clear that there are many types of AML. Each type of AML might have different DNA (gene) changes that affect how it will progress and which treatments might be most helpful. Researchers continue to study how DNA changes specific to different AML types can help us understand how to best treat each person's AML.

Detecting minimal residual disease

In recent years, highly sensitive tests have been developed to detect even the smallest amount of leukemia left after treatment (known as minimal residual disease, or MRD), even when there are so few leukemia cells left that they can't be found by routine bone marrow tests.

Multiparameter flow-cytometry (MFC), quantitative polymerase chain reaction (qPCR), and next-generation sequencing (NGS) are tests that can be used to identify even very small numbers of AML cells in a sample. These tests are useful in determining how completely the treatment has destroyed the AML cells.

Studies are continuing on which test to use and how to best use the information from these tests. The presence of minimal residual disease affects a patient's outlook, as well as if the patient will need further or more intensive treatment.

Improving treatment

Treatment for AML can be very effective for some people, but it doesn't cure everyone, and it can often cause serious or even life-threatening side effects. Studies are looking for more effective and safer treatments for AML. Questions remain on how to sequence and combine drugs approved to treat AML to best fight the disease.

Chemotherapy

[Chemotherapy](#)¹ (chemo) is still the main treatment for most types of AML.

Researchers are looking for the most effective combination of chemo drugs that will also

limit unwanted side effects. This is especially important for older patients who might not be able to tolerate the side effects of currently approved treatments for AML.

The effectiveness of chemo may be limited in some cases because the leukemia cells become resistant to it over time. Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemo. They are also looking at combining chemo with newer types of drugs to see if this might work better.

Stem cell transplants

Researchers continue to refine [stem cell transplants](#)² to try to increase their effectiveness, reduce complications, and determine which patients are likely to be helped by this treatment. Many studies are trying to determine exactly when autologous, allogeneic, and mini-transplants might best be used.

Targeted therapy drugs

Chemo drugs can help many people with AML, but these drugs don't always cure the disease. Newer [targeted drugs](#)³ that specifically attack some of the gene changes seen in AML cells have become an important part of treatment for some people. These drugs don't work the same way as standard chemotherapy drugs. Some examples include:

FLT3 inhibitors. In some people with AML, the leukemia cells have a change (mutation) in the *FLT3* gene. Drugs called FLT3 inhibitors target AML cells with this gene change. FLT3 inhibitors such as midostaurin (Rydapt), quizartinib (Vanflyta), and gilteritinib (Xospata) are now approved to treat people whose AML cells have an *FLT3* mutation. Several other FLT3 inhibitors are now being studied as well..

IDH inhibitors. In some people with AML, the leukemia cells have a mutation in the *IDH1* or *IDH2* gene, which stops the cells from maturing properly. IDH inhibitors can help the leukemia cells mature into normal blood cells. Some of these drugs, such as enasidenib (Idhifa), olutasidenib (Rezlidhia), and ivosidenib (Tibsovo), are now approved to treat AML with certain *IDH* gene mutations. Several other IDH inhibitors are now being studied as well.

BCL-2 inhibitors. Some people with AML have leukemia cells that make too much of a protein called BCL-2. Leukemia cells that overexpress BCL-2 tend to be harder to kill with chemo drugs. BCL-2 inhibitors prevent the BCL-2 protein from working in cancer cells. Venetoclax (Venclexta) is a BCL-2 inhibitor that has been approved to treat AML with BCL-2 overexpression. Several other BCL-2 inhibitors are being studied as well.

Immunotherapy drugs

Immunotherapy works to boost the body's immune system to help fight off or destroy cancer cells.

Bispecific antibodies. A bispecific antibody consists of two antibodies that each attach to a different target, so that two cells can be brought close together. One antibody is usually designed to attach to a target on the leukemia cell, while the other is designed to attach to a target on an immune cell (for example, T cells). When the bispecific antibody brings the cancer cell and immune cell together, your immune system is alerted and starts to fight the cancer cell. Several bispecific antibodies are now being studied for use against AML.

Antibody-drug conjugates (ADC). An ADC is a drug that consist of two parts: an antibody designed to attach to a surface protein on cancer cells and a toxin meant to kill the cancer cells. When ADCs are injected into the body, they act like a homing device, bringing the drug directly to the cancer cells, which kills them. ADCs are already used to treat some types of cancer, and some ADCs are now being studied for use against AML.

Immune checkpoint inhibitors. An important part of the immune system is its ability to keep itself from attacking other normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. Drugs called immune checkpoint inhibitors (ICIs) target these checkpoints and are already used in many other cancers. They continue to be studied for use in AML, especially if combined with chemo or targeted therapy drugs.

Chimeric antigen receptor (CAR) T-cell therapy. For this therapy, immune cells called T cells are removed from the person's blood and altered in the lab so they have specific substances (called **chimeric antigen receptors**, or **CARs**) that will help them attach to leukemia cells. The T cells are then grown in the lab and infused back into the person's blood, where they can now seek out the leukemia cells and attack them.

This therapy has been shown to work in other types of blood cancers. However, it's not yet clear if it will work against AML. Researchers are continuing to study how this therapy can be used to treat AML.

Hyperlinks

1. www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/chemotherapy.html
2. www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/bone-marrow-stem-cell-transplant.html
3. www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/targeted-therapy.html

References

Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. *J Hematol Oncol*. 16, 29 (2023). <https://doi.org/10.1186/s13045-023-01424-6>.

Dekker SE, Rhea D, Cayuela J-M, Arnhardt I, Leonard J, Heuser M. Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia. DOI: 10.1200/EDBK_390010 *American Society of Clinical Oncology*. Educational Book 43 (June 13, 2023)

Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. *Ann Oncol*. 2016;27(5):770-778.

Kebriaei P, de Lima M, Estey EH, Champlin R. Chapter 107: Management of Acute Leukemias. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Last Revised: September 19, 2023

Written by

The American Cancer Society medical and editorial content team
(<https://www.cancer.org/cancer/acs-medical-content-and-news-staff.html>)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy (www.cancer.org/about-us/policies/content-usage.html).

cancer.org | 1.800.227.2345